A Retrospective Study Evaluating The Efficacy And Toxicity Of 68Ga Prostate-Specific Membrane Antigen (PSMA) PET-CT Guided Radiotherapy (RT) In The Treatment Of Oligometastatic Prostate Cancer

Trial Profile

A Retrospective Study Evaluating The Efficacy And Toxicity Of 68Ga Prostate-Specific Membrane Antigen (PSMA) PET-CT Guided Radiotherapy (RT) In The Treatment Of Oligometastatic Prostate Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top